Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Invest. clín ; Invest. clín;33(2): 61-7, 1992. tab
Artigo em Espanhol | LILACS | ID: lil-121956

RESUMO

Nitrendipine (NIT), a new potent calcium channel blockingagent, was administered to a patient with essential severe (191/119 mm Hg), refractory, and resistant hypertension (HT) to conventional triple drug regime. Three previous pregnancies had been insuccessful in the past 4 years because of uncontrollable HT and repeated hypertensive crisisses. NIT (20 mg tablets) was given PO as a single morning dose and 15 months after BP control, she became pregnant again. With a 20 mg/day dose of NIT throughout pregnancy, a healthy 2400 g. 47 cm male boy was delivered by a non-emergency cesarean section at 37 weeks pregnancy. Both mother and con remain normal months after birth. The results suggest NIT may be considered as an alternative for this type of patients and should be studied in clinical trials


Assuntos
Adulto , Humanos , Feminino , Hipertensão/terapia , Hipertensão , Nitrendipino/uso terapêutico , Gravidez/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA